Gunter von Minckwitz

Gunter von Minckwitz leads the German Breast Group and has been central to establishing pathological complete response as a validated surrogate endpoint in neoadjuvant breast cancer trials through meta-analytic work and the CTNeoBC collaboration. He led GeparSixto and multiple GBG trials examining neoadjuvant intensification for TNBC and HER2-positive breast cancer. His research on residual disease management has informed the use of capecitabine (CREATE-X) and T-DM1 in the post-neoadjuvant setting. Von Minckwitz has co-authored major international breast cancer guidelines and is widely regarded as a world authority on neoadjuvant trial design.